BioStem Technologies

BioStem Technologies BioStem Technologies is a leading manufacturer and distributor of superior perinatal tissue products

In our AATB® accredited, FDA registered, cGMP compliant lab, we strive to provide products and services which not only meet but exceed, Current Good Tissue Practice requirements.

05/29/2026

🚀 We’re growing at BioStem Technologies — and we’re looking for top talent to grow with us!

We’re currently hiring for a Product Manager role to help drive innovation in regenerative medicine and advanced wound care. If you’re passionate about bringing cutting-edge products to market and making an impact in healthcare, we’d love to hear from you.

And that’s not all — we have several additional openings across multiple departments as we continue expanding our team.

At BioStem, you’ll join a fast-paced, mission-driven company focused on transforming patient outcomes through innovative biologics and regenerative technologies.

📍 Explore all open positions and apply here:
https://hubs.ly/Q04j9-ST0

05/27/2026

We’re excited to announce that BioStem Technologies will be exhibiting at WOCNext® 2026 in Indianapolis, Indiana, May 31 – June 2!

As the premier event for wound, ostomy, and continence care professionals, WOCNext brings together clinicians, innovators, and industry leaders focused on advancing patient outcomes through evidence-based care.

Stop by our booth to learn how BioStem’s innovative allograft technologies and proprietary tissue processing methods are helping redefine wound care and support clinicians treating complex wounds. We’re looking forward to connecting with healthcare professionals from across the country and discussing what’s next in advanced wound care.

📍 WOCNext® 2026
📅 May 31 – June 2, 2026
🏙️ Indianapolis, Indiana - Booth 1624

We’ll see you there!

This Memorial Day, we pause to honor and remember the brave men and women who made the ultimate sacrifice for our freedo...
05/25/2026

This Memorial Day, we pause to honor and remember the brave men and women who made the ultimate sacrifice for our freedom. Their courage, selflessness, and unwavering dedication to our country will never be forgotten.

To all who gave everything for this nation, and to the families who carry their legacy forward, we thank you.

BioStem Technologies has announced a $2.5 million private placement financing with its first institutional investor — an...
05/22/2026

BioStem Technologies has announced a $2.5 million private placement financing with its first institutional investor — another major milestone as the company continues strengthening its balance sheet and advancing toward a Nasdaq uplisting.

“This transaction marks continued progress in the ex*****on of our capital markets strategy,” said Chairman & CEO Jason Matuszewski.

Combined with the company’s previously announced debt retirement, this latest move highlights BioStem’s continued focus on building a stronger financial foundation to support long-term expansion in the regenerative medicine space.

Read the full release: https://hubs.ly/Q04hCBSS0

BioStem Technologies continues to strengthen its position as a leader in regenerative medicine and placental-derived bio...
05/20/2026

BioStem Technologies continues to strengthen its position as a leader in regenerative medicine and placental-derived biologics.

We are proud to announce that the USPTO has issued Notices of Allowance for four new U.S. design patent applications related to our fenestrated human placental allograft technologies, while the European Patent Office has also granted a new patent covering sterile human placental allografts and proprietary manufacturing methods for growth factor-rich placental tissue allografts.

These innovations are designed to support improved fluid management, conformability, tissue integration, and preservation of the natural biological characteristics of placental tissue — helping advance next-generation solutions for wound care, surgical, and regenerative applications.

With more than 70 patents in our growing global portfolio, BioStem remains committed to driving innovation that helps clinicians deliver better outcomes for patients.

“This milestone reflects our continued focus on protecting the innovation behind our advanced perinatal tissue allograft technologies.”
— Jason Matuszewski, CEO, BioStem Technologies

Click here for full release: https://hubs.ly/Q04hjRH_0

🚀 We’re Growing at BioStem Technologies — Join The Stem! 🚀BioStem continues to expand, and we’re looking for passionate,...
05/20/2026

🚀 We’re Growing at BioStem Technologies — Join The Stem! 🚀

BioStem continues to expand, and we’re looking for passionate, driven professionals to join our mission of advancing regenerative medicine and wound care innovation.

Current Openings Include:

🔹 Sales Representatives
🔹 Product Manager
🔹 Market Access Director

At BioStem, we’re not just building a company — we’re building the future of regenerative medicine. If you’re ready to make an impact with a rapidly growing biotech leader, we’d love to hear from you.

📍 Explore opportunities and apply today: https://hubs.ly/Q04hj0Yy0

05/18/2026

🏃‍♂️💙 Team Stem showed up strong for a great cause!

This past weekend, members of the BioStem family proudly participated in the Florida Panthers’ inaugural Service & Sacrifice 5K in support of our military veterans. 🇺🇸

From crossing the finish line together to sharing laughs along the way, it was an incredible opportunity to support the brave men and women who have served our country while representing BioStem’s commitment to community, healing, and giving back.

Thank you to the Florida Panthers organization for hosting such an impactful event, and congratulations to everyone who participated!

BioStem Technologies ($BSEM) reported Q1 2026 financial results, marking a transformational quarter as the Company integ...
05/14/2026

BioStem Technologies ($BSEM) reported Q1 2026 financial results, marking a transformational quarter as the Company integrated the acquired BioTissue surgical and wound care assets and expanded its hospital-focused commercial strategy.

Highlights from Q1 2026:
🔹 $6.1M in net revenue
🔹 Direct sales force expanded to 35 representatives
🔹 Progress toward planned Nasdaq uplisting
🔹 Strengthened leadership team and operational infrastructure
🔹 Continued integration of BioTissue assets to support long-term growth

“Our achievements in the first quarter have built a foundational platform from which we can deliver durable growth over the long-term.” – Jason Matuszewski, Chairman & CEO

BioStem remains focused on advancing regenerative medicine through its proprietary BioRetain®, CryoTek®, and SteriTek® technologies while expanding adoption of its Neox®, Clarix®, VENDAJE®, and American Amnion™ product portfolio.

Read the full earnings release here: https://hubs.ly/Q04gHBj00

We’re excited to announce that BioStem Technologies will be presenting at the LD Micro Invitational XVI — one of the pre...
05/12/2026

We’re excited to announce that BioStem Technologies will be presenting at the LD Micro Invitational XVI — one of the premier events connecting innovative companies with the investment community.

📍 Luxe Sunset Blvd Hotel, Los Angeles, CA
📅 May 17–19, 2026
🗓 Presentation: Monday, May 18 at 1:30 PM ET

Join us as we share how our advanced amniotic tissue technologies and the proprietary processing methods are redefining advanced wound and surgical care, driving our next phase of growth.

If you’re attending, we’d love to connect.

Address

2836 Center Port Cir
Pompano Beach, FL
33064

Opening Hours

Monday 9am - 5:30pm
Tuesday 9am - 5:30pm
Wednesday 9am - 5:30pm
Thursday 9am - 5:30pm
Friday 9am - 5:30pm

Telephone

+19543808342

Website

Alerts

Be the first to know and let us send you an email when BioStem Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to BioStem Technologies:

Shortcuts

Share

Category